R. Gentilella

1.2k total citations
34 papers, 906 citations indexed

About

R. Gentilella is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, R. Gentilella has authored 34 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Molecular Biology and 7 papers in Surgery. Recurrent topics in R. Gentilella's work include Diabetes Treatment and Management (20 papers), Diabetes Management and Research (14 papers) and Metabolism, Diabetes, and Cancer (10 papers). R. Gentilella is often cited by papers focused on Diabetes Treatment and Management (20 papers), Diabetes Management and Research (14 papers) and Metabolism, Diabetes, and Cancer (10 papers). R. Gentilella collaborates with scholars based in Italy, United States and France. R. Gentilella's co-authors include V. Pechtner, Agostino Consoli, Antonio Ceriello, G. Reach, Andrea Rossi, Cristina Bianchi, Carlo Maria Rotella, Laura De Marinis, Antonio Bianchi and D. Valle and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Journal of Bone and Mineral Research and International Journal of Obesity.

In The Last Decade

R. Gentilella

34 papers receiving 887 citations

Peers

Countries citing papers authored by R. Gentilella

Since Specialization

Citations

This map shows the geographic impact of R. Gentilella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Gentilella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Gentilella more than expected).

Fields of papers citing papers by R. Gentilella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Gentilella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Gentilella. The network helps show where R. Gentilella may publish in the future.

Co-authorship network of co-authors of R. Gentilella

This figure shows the co-authorship network connecting the top 25 collaborators of R. Gentilella. A scholar is included among the top collaborators of R. Gentilella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Gentilella. R. Gentilella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics 2021 ·Diabetes Therapy ·Luis‐Emilio García‐Pérez, Kristina S. Boye, Myriam Rosilio, Heike Jung, (unknown), Kirsi Norrbacka, Marco Orsini Federici, R. Gentilella, Bruno Guerci, Francesco Giorgino, Ulrich Aigner, Hélène Sapin	5
2	Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c 2020 ·Journal of Diabetes and its Complications ·Irene Romera, Ignacio Conget, Luis Alberto Vázquez, R. Gentilella, Jérémie Lebrec, Esteban Jódar, Jesús Reviriego	3
3	Short‐ and long‐term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism 2019 ·Journal of Neuroendocrinology ·Antonio Bianchi, Antonella Giampietro, Linda Tartaglione, Sabrina Chiloiro, R. Gentilella, (unknown), Carmelo Anile, Alessandro Olivi, Alfredo Pontecorvi, Laura De Marinis	17
4	PDB116 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS 2019 ·Value in Health ·(unknown), Hélène Sapin, Kirsi Norrbacka, Bruno Guerci, Francesco Giorgino, Ulrich Aigner, (unknown), R. Gentilella, (unknown), Heike Jung, Myriam Rosilio, Kristina S. Boye	3
5	PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE 2019 ·Value in Health ·Kristina S. Boye, (unknown), Hélène Sapin, Myriam Rosilio, (unknown), (unknown), Heike Jung, R. Gentilella, Ulrich Aigner, Bruno Guerci, Francesco Giorgino, Kirsi Norrbacka	1
6	Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index 2019 ·Diabetes Obesity and Metabolism ·R. Gentilella, Giorgio Sesti, Luis Alberto Vázquez, Hélène Sapin, Victoria Reed, Irene Romera, Paolo Pozzilli	11
7	Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same? 2018 ·Diabetes/Metabolism Research and Reviews ·R. Gentilella, V. Pechtner, (unknown), Agostino Consoli	181
8	Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes 2018 ·Patient Preference and Adherence ·Louis S. Matza, Kristina S. Boye, Jessica Jordan, Kirsi Norrbacka, R. Gentilella, (unknown), Chantelle Browne, Marco Orsini Federici, (unknown), Katie D. Stewart	13
9	Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement 2018 ·Patient Preference and Adherence ·Francesco Giorgino, Alfred Penfornis, V. Pechtner, R. Gentilella, (unknown)	54
10	Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes 2017 ·Value in Health ·(unknown), (unknown), (unknown), Kirsi Norrbacka, R. Gentilella, Chantelle Browne, (unknown), (unknown)	1
11	Insulin therapy in neonatal diabetes mellitus: a review of the literature 2017 ·Diabetes Research and Clinical Practice ·Ivana Rabbone, Fabrizio Barbetti, R. Gentilella, (unknown), Riccardo Bonfanti, Claudio Maffeis, Dario Iafusco, Elvira Piccinno	27
12	Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus 2017 ·Diabetes & Metabolism ·G. Reach, V. Pechtner, R. Gentilella, (unknown), Antonio Ceriello	183
13	Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data 2012 ·Expert Opinion on Pharmacotherapy ·Antonio Ceriello, Francesco Cremasco, (unknown), Andrea Rossi, R. Gentilella	7
14	Exenatide: a review from pharmacology to clinical practice 2009 ·Diabetes Obesity and Metabolism ·R. Gentilella, Cristina Bianchi, Andrea Rossi, Carlo Maria Rotella	86
15	Unmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents 2008 ·Journal of Endocrinological Investigation ·Dario Pitocco, D. Valle, Andrea Rossi, R. Gentilella	13
16	Osteoporosis treatment and fracture incidence: the ICARO longitudinal study 2008 ·Osteoporosis International ·S. Adámi, Giancarlo Isaia, G. Luisetto, Salvatore Minisola, L. Sinigaglia, (unknown), D. Agnusdei, R. Gentilella, Ranuccio Nuti, (unknown)	21
17	Opioid dysregulation after biliopancreatic diversion: Effect of naloxone on preprandial and postprandial growth hormone (GH)-releasing hormone-induced GH release in surgically induced weight loss 2001 ·Metabolism ·A. Mancini, Antonio Bianchi, Roberto M. Tacchino, (unknown), Domenico Milardi, R. Gentilella, Antonella Giampietro, Alessandra Fusco, D. Valle, Laura De Marinis	1
18	Effects of galanin on growtn hormone and prolactin secretion in anorexia nervosa 2000 ·Metabolism ·Laura De Marinis, A. Mancini, Domenico Valle, Antonio Bianchi, R. Gentilella, Domenico Milardi, (unknown), Andrea Giustina	13
19	Evaluation of pre- and postprandial growth hormone (GH)-releasing hormone-induced GH response in subjects with persistent body weight normalisation after biliopancreatic diversion 1998 ·International Journal of Obesity ·Laura De Marinis, Antonio Mancini, D. Valle, (unknown), Antonio Bianchi, R. Gentilella, (unknown), M Castagneto, G Gasbarrini	8
20	Physiological role of the opioid-cholinergic interaction in growth hormone neuroregulation: Effect of sex and food intake 1997 ·Metabolism ·Laura De Marinis, Antonio Mancini, Domenico Valle, (unknown), Gianluigi Conte, Antonio Bianchi, (unknown), R. Gentilella, Andrea Giustina	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact